Disagree with your above comment.
PXS has $18.4 million cash sitting in the bank and they will be cashflow positive end of 2021 based of current projections.
This is with the exclusion of milestone payments of $15 million US from their partner Chiesi.
FDA product line in the backend with cashflow positive outlook plus milestones and valued at $0.09 cents a share with only 392 million shares outstanding.
I think those Bollinger bands will squeeze on investors getting in around these prices.
Ann: Appendix 4C - quarterly, page-3
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.002(5.00%) |
Mkt cap ! $57.67M | |||
| Open | High | Low | Value | Volume |
| 4.0¢ | 4.3¢ | 4.0¢ | $48.01K | 1.160M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1025000 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 461843 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SNT (ASX) Chart |